Page 157 - Haematologica Vol. 110 - January 2025

ARTICLE - R-GemOx+Atezo in R/R transformed DLBCL T. Othman et al.
Haematologica | 110 January 2025
149
Table 3. Responses to the rituximab, gemcitabine, oxaliplatin and atezolizumab treatment regimen based on prior lines of therapy.
Patient N of prior ID lines
N of prior lines for transformed lymphoma
Response to
Response to last line of therapy
Last line treating indolent or transformed lymphoma
Time from last line of therapy to enrollment
Response to R-GemOx+ Atezo
1 2
1
Yes CR
Bendamustine/ Obinutuzumab
PR
Indolent
N/A
7.1 months
PR
2 1
3 1
1 1
Yes PD Yes CR
DA-EPOCH-R R-CHOP
PD CR
Transformed Transformed
N/A N/A
27 days 15.7 years
CR CR
4 3
0
No N/A
Venetoclax/ obinutuzumab
CR
Indolent
N/A
6.4 months
PD
5 2
6 1
7 7
0 1 1
No N/A Yes SD Yes PD
Ibrutinib
CR CR PD
Indolent Transformed Transformed
N/A N/A N/A
19 days
PD PD PD
8 4
9 2
10 1
4 0 1
Yes CR No N/A No N/A
Axicabtagene ciloleucel
CR PD CR
Transformed Indolent Indolent
CR N/A N/A
1.1 years 1.1 months 4.3 years
PR N/A SD
11 3
1
Yes PR
Bendamustine/ rituximab
SD
Indolent
N/A
23 days
CR
12 3
13 1
14 1
15 7
16 1
17 1
1 1 1 4 1 1
Yes PR Yes PR Yes PR Yes PD Yes CR Yes CR
R-CHOP
PR
PR
PR
PD
CR
CR
Transformed Transformed Transformed Transformed Transformed Transformed
N/A N/A N/A CR N/A N/A
2.5 months 1.5 months 9.1 months 23 days 1.7 years 2.3 years
PD
PR
CR
PD
CR
CR
18 3
1
Yes CR
Bendamustine/ Obinutuzumab
CR
Indolent
N/A
1.9 years
PD
19 4
20 3
21 1
22 1
23 1
2 1 1 1 1
Yes SD Yes PR Yes PD Yes CR Yes PR
ICE
PD PR PD CR PR
Transformed Transformed Transformed Transformed Transformed
N/A N/A N/A N/A N/A
1.5 months 5.4 months 1.7 months 1.2 years 5.8 months
PD PR PD CR PR
24 4
1
Yes CR
Bendamustine/ rituximab
SD
Indolent
N/A
3.8 years
PR
25 2
26 1
27 1
1 1 1
Yes CR Yes CR Yes CR
R-CHOP R-CHOP R-CHOP
CR CR CR
Transformed Transformed Transformed
N/A N/A N/A
1.2 years 1.8 years 6.4 years
CR PR CR
Prior R-CHOP or anthracycline DA-EPOCH-R
Last line of therapy
Response to CAR T cells
R-CHOP
25 days 1.3 months
DA-EPOCH-R
Venetoclax
Bendamustine/ rituximab
R-CHOP
R-CHOP
Clinical Trial
R-CHOP
DA-EPOCH-R
DA-EPOCH-R
R-CHOP
R-CHOP
DA-EPOCH-R
ID. Identity; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; DA-EPOCH-R: dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; CAR: chimeric antigen receptor; R-GemOx+Atezo: rituximab, gemcitabine, oxaliplatin, and atezolizumab; CR: complete response; PR: partial response; N/A: not applicable; PD: progressive disease; SD: stable disease; ICE: ifosfamide, carboplatin, and etoposide.